Anzeige
Meldung des Tages: UBS spricht von der dritten großen Lithium-Preisphase - und EMP setzt bereits operativ um

Co-Diagnostics Aktie News

Aktie
WKN:  A41UNJ ISIN:  US1897632048 US-Symbol:  CODX
2,31 $
-0,04 $
-1,70%
1,9511 € 06.02.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

Co-Diagnostics News

05.02.26 - PR Newswire
Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
Co-​Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument PR Newswire
04.02.26 - PR Newswire
Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Co-​Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform PR Newswire
12.01.26 - PR Newswire
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
Co-​Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships PR Newswire
30.12.25 - PR Newswire
Co-Diagnostics Announces Reverse Stock Split
Co-​Diagnostics Announces Reverse Stock Split PR Newswire
29.12.25 - PR Newswire
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Co-​Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies PR Newswire
18.12.25 - PR Newswire
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-​Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India PR Newswire
17.12.25 - PR Newswire
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
Co-​Diagnostics Performs Analysis of Influenza Co-​Primers® to Confirm Reactivity Against Flu A H3N2 Mutation PR Newswire
09.12.25 - PR Newswire
Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025
Co-​Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-​of-Care Testing 2025 PR Newswire
08.12.25 - PR Newswire
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Co-​Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India PR Newswire
20.11.25 - PR Newswire
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Co-​Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health PR Newswire
18.11.25 - PR Newswire
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
Co-​Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-​of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA PR Newswire
13.11.25 - PR Newswire
Co-Diagnostics Reports Third Quarter 2025 Financial Results
Co-​Diagnostics Reports Third Quarter 2025 Financial Results PR Newswire
12.11.25 - PR Newswire
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
Utah Governor Cox and BioUtah Recognize Co-​Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia PR Newswire
05.11.25 - PR Newswire
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
Co-​Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd PR Newswire
03.11.25 - PR Newswire
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Co-​Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform PR Newswire
31.10.25 - PR Newswire
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast
Co-​Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast PR Newswire
30.10.25 - PR Newswire
Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia
Co-​Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia PR Newswire
29.10.25 - PR Newswire
Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Co-​Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-​The-Market Under Nasdaq Rules PR Newswire
28.10.25 - PR Newswire
Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Co-​Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-​The-Market Under Nasdaq Rules PR Newswire
27.10.25 - PR Newswire
Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East
Co-​Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle ...

Newssuche

Videos

newspaper
06.02.26 +6,46%
Technical Trading: Gold kurzfristig Long
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »